Mode
Text Size
Log in / Sign up
N/A N=705

Women's Improvement of Sexual Health (WISH) Demonstration Project

Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis · Urinary Tract Infections

Enrolled (actual)
705
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Urogenital infection point-of-care tests (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Janneke van de Wijgert
Primary completion
Mar 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)
396; 378; 399; 216; 541; 505
PRIMARY
Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)
107; 107; 107; 41; 0; 100
PRIMARY
Performance of Syndromic Management With or Without Integration of Point-of-care Tests
58.3; 71.7; 44.7; 100; 8.9; 100

Summary

The current standard of care for urogenital infections in Rwanda is syndromic management. Many urogenital infections are asymptomatic and therefore completely missed, and the management of vaginal discharge syndrome is known to be suboptimal. The primary objective of this study is to evaluate whether it is feasible to improve urogenital infection care in high risk women in Kigali, Rwanda, using point of care (POC) diagnostic testing for HIV, Trichomonas vaginalis (TV), and bacterial vaginosis (BV) in all women; POC testing for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and syphilis in pregnant women and women assessed to be at high risk for these infections using a risk scoring questionnaire; and management of vaginal candidiasis, urinary tract infection (UTI), genital ulcers/inguinal bubos, and lower abdominal pain in women reporting relevant symptoms. The secondary objectives of this study are 1) to evaluate the performance and 2) to obtain the opinions of Rwandan stakeholders.

Eligibility Criteria

Inclusion Criteria

  • Female, at least 18 years old (no upper age limit)
  • At high risk of HIV/STIs, defined as having had more than one sexual partner in the last 12 months OR having been treated for an STI in the last 12 months
  • Willing and able to provide written informed consent.

Exclusion Criteria

  • Already participated in this study before (each woman can only participate once)
  • Participating in another health intervention study
  • For any other reason as judged by the Principal Investigator (these reasons will be recorded)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03045809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search